Thrivent Financial for Lutherans Purchases Shares of 38,457 Cryoport, Inc. (NASDAQ:CYRX)

Thrivent Financial for Lutherans acquired a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 38,457 shares of the company’s stock, valued at approximately $299,000. Thrivent Financial for Lutherans owned approximately 0.08% of Cryoport at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. AlphaQuest LLC boosted its holdings in Cryoport by 81.3% in the fourth quarter. AlphaQuest LLC now owns 52,714 shares of the company’s stock worth $410,000 after acquiring an additional 23,631 shares in the last quarter. Heritage Investors Management Corp bought a new position in shares of Cryoport in the 4th quarter worth $122,000. Olympiad Research LP bought a new position in shares of Cryoport in the 4th quarter worth $103,000. Rhumbline Advisers grew its position in Cryoport by 2.9% in the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares during the period. Finally, Penbrook Management LLC increased its stake in Cryoport by 6.0% during the 4th quarter. Penbrook Management LLC now owns 52,570 shares of the company’s stock valued at $409,000 after purchasing an additional 2,975 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 19,830 shares of company stock worth $118,353. Insiders own 10.10% of the company’s stock.

Cryoport Stock Performance

Shares of Cryoport stock opened at $5.34 on Friday. The firm has a market capitalization of $266.52 million, a P/E ratio of -1.58 and a beta of 1.67. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $6.45 and its 200 day simple moving average is $7.24. Cryoport, Inc. has a 12 month low of $4.58 and a 12 month high of $19.00.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the business posted ($0.29) EPS. As a group, analysts anticipate that Cryoport, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CYRX shares. Roth Mkm reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Cryoport in a research note on Tuesday. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Monday, March 31st. Finally, UBS Group increased their price objective on Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Cryoport presently has an average rating of “Moderate Buy” and a consensus price target of $11.83.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.